Page 34 - 79_02
P. 34
AS101,
un
interesante
fármaco
multipotente
al
tratamiento
de
alguno
de
los
problemas
terapéuticos
en
los
que
ha
demostrado
su
posible
aplicación.
Referencias
1. Kalich--Philosoph,
L.;
Roness,
H.;
Carmely,
A.;
Fishel--Bartal,
M.;
Ligumsky,
H.;
Paglin,
S.;
Wolf,
I.;
Kanety,
H.;
Sredni,
B.;
Meirow,
D.;
(2013)
“Cyclophosphamide
Triggers
Follicle
Activation
and
“Burnout”;
AS101
Prevents
Follicle
Loss
and
Preserves
Fertility”,
Sci.
Transl.
Med.
5,
185ra62.
2. Brydoy,
M.;
Fossa,
S.
D.;
Dahl,
O.;
Bjøro
T.;
(2007)
“Gonadal
dysfunction
and
fertility
problems
in
cancer
survivors”;
Acta
Oncol.
46,
480--9.
3. Nogueira,
C.
W.;
Zeni,
G.;
Rocha,
J.
B.T.;
(2004)
“Organoselenium
and
organotellurium
compounds:
toxicology
and
pharmacology”,
Chem.
Rev.,
104,
6255--6285.
4. Yosef,
S.;
Brodsky,
M.;
Sredni,
B.;
Albeck,
A.;
Albeck
M.;
(2007)
“Octa--O--bis--(R,R)--Tartarate
Ditellurane
(SAS)
--
a
novel
bioactive
organotellurium(IV)
compound:
synthesis,
characterization,
and
protease
inhibitory
activity”;
ChemMedChem.,
2,
1601--1606.
5. Cunha,
R.
L.;
Urano,
M.
E.;
Chagas,
J.
R.;
Almeida,
P.
C.;
Bincoletto,
C.;
Tersariol,
I.
L.;
Comasseto,
J.
V.;
(2005)
“Tellurium--based
cysteine
protease
inhibitors:
evaluation
of
novel
organotellurium
(IV)
compounds
as
inhibitors
of
human
cathepsin
B”;
Bioorg.
Med.
Chem.
Lett.,
15,
755–760.
6. Lima,
C.
B.;
Arrais--Silva,
W.
W.;
Cunha,
R.
L.,
Giorgio,
S.;
(2009)
“A
novel
organotellurium
compound
(RT--01)
as
a
new
antileishmanial
agent”,
Korean
J.
Parasitol.,
47,
213--218.
7. (a)
Kalechman,
Y.;
Sredni,
B.;
(1996)
”Differential
effect
of
the
immunomodulator
AS101
on
B7--1
and
B7--2
costimulatory
molecules:
role
in
the
antitumoral
effects
of
AS101”;
J.
Immunol.,
157,
589--597.
(b)
Sredni,
B.,
Tichler,
T.;
Shani,
A.;
Catane,
R.;
Kaufman,
B.
;
Strassmann,
G.;
Albeck,
M.;
Kalechman,
Y.;
(1996)
“Predominance
of
TH1
response
in
tumor--bearing
mice
and
cancer
patients
treated
with
AS101”;
J.
Natl.
Cancer
Inst.
88,
1276--1284.
(c)
Kalechman,
Y.,
Strassmann,
G.;
Albeck,
M.;
Sredni,
B.;
(1998)
“Upregulation
by
ammonium
trichloro(dioxoethylene--O,O’--)tellurate
(AS101)
of
Fas/Apo--
1
expression
on
B16
melanoma
cells:
implications
for
the
antitumor
effects
of
AS101”; J.
Immunol.,
161,
3536--3542.
(d)
Kalechman,Y.;
Gafter,
U.;
Gal,
R.;
Rushkin,
G.;
Yan,
D.;
Albeck,
M.;
Sredni,
B.;
(2002)
“Anti--IL--10
Therapeutic
Strategy
Using
the
Immunomodulator
AS101
in
Protecting
Mice
from
Sepsis--Induced
Death:
Dependence
on
Timing
of
Immunomodulating
Intervention”,
J.
Immunol.,
169,
384--392.
8. (a)
Sredni,
B.;
Caspi,
R.
R.;
Klein,
A.;
Kalechman,
Y.;
Danziger,
Y.;
Benya'akov,
M.;
Tamari,
T.;
Shalit,
F.;
Albeck,
M.;
(1987)
“A
new
immunomodulating
compound
(AS--101)
with
potential
therapeutic
application”; Nature,
330,
173--176.
(b)
Brodsky,
M.;
Halpert,
G.;
Albeck,
M.;
Sredni,
B.;
(2010)
“The
anti--inflammatory
effects
of
the
tellurium
redox
modulating
compound,
AS101,
are
associated
with
regulation
of
NFkappaB
signaling
pathway
and
nitric
oxide
induction
in
macrophages”;
J.
Inflamm.
(Lond),
7,
3.
9. Sredni,
B.;
(2012)
“Immunomodulating
tellurium
compounds
as
anti--cancer
agents”;
Semin.
Cancer
Biol.,
22,
60--69.
10. (a)
Sredni,
B.;
Weil,
M.;
Khomenok,
G.;
Lebenthal,
I.;
Teitz,
S.;
Mardor,
Y.;
Ram,
Z.;
Orenstein,
A.;
Kershenovich,
A.;
Michowiz,
S.;
Cohen,
Y.
I.;
Rappaport,
Z.
H.;
Freidkin,
I.;
Albeck,
M.;
Longo,
D.
L.;
Kalechman,
Y.;
(2004)
“Ammonium
trichloro(diosoethylene--O,O’--
tellurate
(AS101)
sensitizes
tumors
to
chemotherapy
by
inhibitng
the
tumor
interleukin
10
autocrine
loop”;
Cancer
Res.,
64,
1843--1852.
(b)
hayan,
R.;
Shpungin,
S.;
Malovani,
H.;
Albeck,
M.;
Okun,
E.;
Nir,
U.;
Sredni,
B.;
(2007)
“Novel
involvement
of
the
immunomodulator
AS101
in
IL--10
signaling,
via
the
tyrosine
kinase
Fer”,
Ann.
N.
Y.
Acad.
Sci.,
1095,
240--250.
11. (a)
Daniel--Hoffmann,
M.;
Albeck,
M.;
Sredni,
B.;
Nitzan,
Y.;
(2009)
Arch.
Microb.,
191,
631--
638.
(b)
Daniel--Hoffmann,
M.;
Sredni,
B.;
Nitzan,
Y.;
(2012)
“Bactericidal
activity
of
the
205
